KR102250412B1 - 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화 - Google Patents

멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화 Download PDF

Info

Publication number
KR102250412B1
KR102250412B1 KR1020190053334A KR20190053334A KR102250412B1 KR 102250412 B1 KR102250412 B1 KR 102250412B1 KR 1020190053334 A KR1020190053334 A KR 1020190053334A KR 20190053334 A KR20190053334 A KR 20190053334A KR 102250412 B1 KR102250412 B1 KR 102250412B1
Authority
KR
South Korea
Prior art keywords
mel
dkla
tumor
conjugate
succinimidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020190053334A
Other languages
English (en)
Korean (ko)
Other versions
KR20190127609A (ko
Inventor
배현수
이찬주
정진현
이도하
김정동
Original Assignee
트윈피그바이오랩(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트윈피그바이오랩(주) filed Critical 트윈피그바이오랩(주)
Publication of KR20190127609A publication Critical patent/KR20190127609A/ko
Application granted granted Critical
Publication of KR102250412B1 publication Critical patent/KR102250412B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020190053334A 2018-05-04 2019-05-07 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화 Active KR102250412B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180051800 2018-05-04
KR20180051800 2018-05-04

Publications (2)

Publication Number Publication Date
KR20190127609A KR20190127609A (ko) 2019-11-13
KR102250412B1 true KR102250412B1 (ko) 2021-05-17

Family

ID=68386643

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190053334A Active KR102250412B1 (ko) 2018-05-04 2019-05-07 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화

Country Status (8)

Country Link
US (1) US11484601B2 (https=)
EP (1) EP3789041A4 (https=)
JP (1) JP7234349B2 (https=)
KR (1) KR102250412B1 (https=)
CN (1) CN112533640B (https=)
AU (1) AU2019264092B2 (https=)
CA (1) CA3099434C (https=)
WO (1) WO2019212324A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240009269A1 (en) * 2020-11-20 2024-01-11 The Johns Hopkins University Membrane-active peptides and methods for reversible blood- brain barrier opening
CA3153060A1 (en) * 2021-05-07 2022-11-07 Twinpig Biolab, Inc. Peptides targeting macrophages, and conjugates, compositions, and uses thereof
US20220354957A1 (en) * 2021-05-07 2022-11-10 Twinpig Biolab, Inc. Peptides targeting macrophages, and conjugates, compositions, and uses thereof
CN113336828B (zh) * 2021-06-30 2022-03-25 中国海洋大学 抗菌肽yhx-3及其组合物和应用
CN114437193A (zh) * 2022-01-29 2022-05-06 陕西未来多肽生物科技有限公司 一种金-蜂毒肽纳米杂化物及其应用
KR20230144960A (ko) * 2022-04-07 2023-10-17 트윈피그바이오랩(주) 신규 펩타이드 기반 면역항암제
WO2023204329A1 (ko) * 2022-04-22 2023-10-26 트윈피그바이오랩(주) 신규 펩타이드 기반 면역항암제
CN115317622B (zh) * 2022-08-12 2025-08-22 青岛科技大学 一种抗肿瘤多肽偶联药物的制备及其应用
CN116589555B (zh) * 2023-03-31 2024-02-06 广东医科大学 一种细胞穿梭肽及其应用
CN119896743B (zh) * 2023-10-26 2025-09-26 华南理工大学 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用
KR20250091126A (ko) * 2023-12-12 2025-06-20 트윈피그바이오랩(주) 신규 펩타이드를 유효성분으로 포함하는 항암제와의 병용투여를 위한 항암 조성물
CN120053399A (zh) * 2025-02-27 2025-05-30 滁州学院 一种蜂毒肽靶向制剂及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
CA2543072A1 (en) * 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
BRPI0923283A2 (pt) 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
KR20110117789A (ko) 2010-04-22 2011-10-28 대한민국(농촌진흥청장) 멜리틴을 함유하는 동맥경화 치료용 조성물
KR20110117788A (ko) 2010-04-22 2011-10-28 대한민국(농촌진흥청장) 멜리틴을 포함하는 섬유아세포-유사-활막세포의 활성을 억제하는 조성물
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
KR101935095B1 (ko) * 2015-07-31 2019-01-04 이화여자대학교 산학협력단 신규한 세포투과성 펩타이드
CN106699896B (zh) * 2016-12-05 2020-06-05 华中科技大学同济医学院附属协和医院 一种可自组装成水凝胶的肿瘤杀伤性多肽及其应用
KR102073273B1 (ko) 2017-08-23 2020-03-02 (주) 레느스랩 멜리틴을 포함하는 m2형 종양관련 대식세포 제거용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Letters, 2017, 420, 16-31
J. Peptide Res., 1999, 53, 82-90
The Journal of Immunology, 2018.05.01, 200권 (1 Supplement), 56.22, 요약*

Also Published As

Publication number Publication date
US20210244823A1 (en) 2021-08-12
CA3099434A1 (en) 2019-11-04
AU2019264092A8 (en) 2021-01-07
WO2019212324A1 (ko) 2019-11-07
US11484601B2 (en) 2022-11-01
EP3789041A4 (en) 2022-07-13
CN112533640B (zh) 2025-02-28
CN112533640A (zh) 2021-03-19
EP3789041A1 (en) 2021-03-10
KR20190127609A (ko) 2019-11-13
AU2019264092B2 (en) 2024-02-15
CA3099434C (en) 2023-09-05
AU2019264092A1 (en) 2020-12-24
JP2021526548A (ja) 2021-10-07
JP7234349B2 (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
KR102250412B1 (ko) 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화
US12269902B2 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
Kularatne et al. A CXCR4‐Targeted Site‐Specific Antibody–Drug Conjugate
JP6420459B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
KR102224965B1 (ko) 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
EA035463B1 (ru) Способы и композиции для лечения рака
US20200157151A1 (en) Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
KR20220152383A (ko) 대식세포를 표적으로 하는 펩타이드, 컨쥬게이트, 조성물 및 그의 용도
US20220354957A1 (en) Peptides targeting macrophages, and conjugates, compositions, and uses thereof
US20240156971A1 (en) Methods and sortilin binding conjugate compounds for targeting cancer stem cells
KR102831503B1 (ko) 암 예방 또는 치료를 위한 알부민 결합 전구약물, 이를 포함하는 약학 조성물
JP2017500849A (ja) 細胞透過組成物およびそれを用いる方法
WO2021054448A1 (ja) ペプチド並びにそれを含む細胞融合剤及びがん治療用医薬組成物
Campeiro Potential applications of the cell-penetrating peptide crotamine
JPWO2019138944A1 (ja) 細胞殺傷剤
KR20230144960A (ko) 신규 펩타이드 기반 면역항암제
JPWO2019045025A1 (ja) ワクチン組成物
BR112018010535B1 (pt) Compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20190507

PA0201 Request for examination
PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20200121

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201124

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210420

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210504

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210506

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240429

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250422

Start annual number: 5

End annual number: 5